Key clinical point: The oral iron chelator deferiprone is noninferior to deferoxamine for treating iron overload in patients with sickle cell disease and other rare anemias.
Major finding: Least squares mean change from baseline in liver iron concentration was –4.04 vs. –4.45 mg/g dw with deferiprone vs. deferoxamine.
Study details: A randomized, open-label study of 152 patients.
Disclosures: Dr. Kwiatkowski reported research funding from Terumo, bluebird bio, Novartis, and Apopharma, and consultancy for Imara, bluebird bio, Agios, and Celgene.
Kwiatkowski J et al. ASH 2019, Abstract 618.